Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
NCT02233881 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4222
Last updated 2014-09-09
Summary
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
Atrovent® - inhalets
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-01-31
- Primary Completion
- 2001-11-30
More Related Trials
-
Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
NCT02236715 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT02238184 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis
NCT02233920 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease
NCT02233907 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02232594 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
NCT02231424 ·Status: COMPLETED
-
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
NCT02260011 ·Status: COMPLETED ·Phase: PHASE2
-
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02236169 ·Status: COMPLETED ·Phase: PHASE2
-
Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02244216 ·Status: COMPLETED
-
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01350128 ·Status: COMPLETED ·Phase: PHASE2
-
Actuation Indicator Trial in Patients With COPD
NCT00928746 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01415518 ·Status: COMPLETED ·Phase: PHASE4
-
Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease
NCT02231437 ·Status: COMPLETED
-
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
NCT02552160 ·Status: COMPLETED
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers
NCT02743013 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
NCT02359292 ·Status: COMPLETED ·Phase: PHASE1
-
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
NCT04078126 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172469 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01168310 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices
NCT02184624 ·Status: COMPLETED ·Phase: PHASE4
-
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
NCT02573155 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00274092 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
NCT03836677 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease
NCT00532350 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients
NCT01385696 ·Status: COMPLETED ·Phase: PHASE3